Governance BioMarin Pharmaceutical Inc.

BMRN

US09061G1013

Pharmaceuticals

Real-time Estimate Cboe BZX Other stock markets 20:01:01 13/01/2026 GMT			5-day change	1st Jan Change
54.86 ^USD	-4.95%		-8.46%	-7.47%

10:13am	BioMarin Pharmaceutical Reports Preliminary 2025 Revenue, Details Asset Write-Down	MT
01-12	Biomarin Pharmaceutical Inc estimates $3.2 billion in total revenues for FY - SEC filing	RE

Executive Committee: BioMarin Pharmaceutical Inc.

Manager

Positions heldSince

Alexander Hardy

57 year

Chief Executive Officer	30/11/2023
President	30/11/2023

Gregory Friberg

52 year

Chief Tech/Sci/R&D Officer

29/09/2024

Brian Mueller

52 year

Comptroller/Controller/Auditor	01/09/2025
Director of Finance/CFO	28/01/2020

Kevin Eggan

Chief Tech/Sci/R&D Officer

04/10/2020

C. Guyer

64 year

Chief Tech/Sci/R&D Officer

30/04/2020

Amy Wireman

Human Resources Officer

31/12/2012

Stuart Bunting

Chief Tech/Sci/R&D Officer

Traci McCarty

Investor Relations Contact

George Davis

55 year

General Counsel	29/02/2004
Corporate Secretary	29/02/2004

Composition of the Board of Directors: BioMarin Pharmaceutical Inc.

Director

CommitteesSince

Randy Meier

66 year

Chairman	30/11/2023
Independent Dir/Board Member	12/09/2011

Ian Clark

64 year

Compensation Committee	31/12/2018
Governance Committee	07/07/2024
Nominating Committee	07/07/2024
Governance Committee Chair	31/07/2020
Nominating Committee Chair	31/07/2020
Audit Committee	31/07/2025

Elizabeth Anderson

68 year

Compensation Committee Chair
Governance Committee Chair
Nominating Committee Chair
Governance Committee	09/07/2019
Audit Committee	31/08/2022
Compensation Committee	31/08/2022

Timothy Walbert

59 year

Compensation Committee	31/05/2024
Governance Committee Chair	31/05/2023
Nominating Committee Chair	31/05/2023
Audit Committee	31/03/2024
Governance Committee	31/05/2024
Nominating Committee	31/05/2024

Athena Countouriotis

54 year

Compensation Committee	09/06/2019
Governance Committee	26/12/2023
Nominating Committee	26/12/2023
Audit Committee
Compensation Committee Chair	04/03/2020

Willard Dere

72 year

Compensation Committee	17/07/2016
Audit Committee	18/03/2018
Governance Committee Chair	18/03/2018
Nominating Committee Chair	18/03/2018

Barbara Bodem

58 year

Audit Committee	31/12/2023
Governance Committee	31/12/2023
Nominating Committee	31/12/2023
Finance Committee

May Kin Ho

73 year

Audit Committee	28/02/2018
Governance Committee	31/03/2021
Nominating Committee	31/03/2021

Mark Enyedy

62 year

Audit Committee	26/12/2023
Governance Committee	19/05/2025
Nominating Committee	19/05/2025

Robert Hombach

60 year

Compensation Committee	19/03/2022
Audit Committee Chair	10/03/2025

Alexander Hardy

57 year

Director/Board Member

30/11/2023

Latest Appointments: BioMarin Pharmaceutical Inc.

01-12	BioMarin Pharmaceutical Names Arpit Dave Chief Digital and Information Officer	MT
01-12	BioMarin Pharmaceutical Inc. Appoints Arpit Davé as Executive Vice President and Chief Digital and Information Officer	CI
12-17	BioMarin Pharmaceutical Inc. Appoints Rashmi Ramchandani as Chief Accounting Officer, Effective January 19, 2026	CI
11-11	Medincell Appoints Dr Grace Kim, Chief Strategy Officer, U.S. Finance, to Advance into Next Stage of US Capital Growth	CI
14/10/25	GeneDx Holdings Corp. Appoints Dr. Mimi Lee as Chief Precision Medicine Officer	CI
11/08/25	BioMarin Pharmaceutical Inc. Announces Resignation of Chief Accounting Officer ,Effective September 2, 2025	CI
01/08/25	Biomarin Pharmaceutical announces appointment of Ian T. Clark to board of directors	RE

More news

Former Officers and Directors: BioMarin Pharmaceutical Inc.

Insider

Positions held

SinceUntil

Elaine Heron

Director/Board Member	30/06/2002	19/05/2025
Independent Dir/Board Member	12/09/2011	19/05/2025

David Pyott

Director/Board Member	03/01/2016	19/05/2025
Independent Dir/Board Member	03/01/2016	19/05/2025

V. Lawlis

Director/Board Member	31/05/2007	20/05/2024
Independent Dir/Board Member	12/09/2011	20/05/2024

Dennis Joseph Slamon

Director/Board Member	20/03/2014	20/05/2024
Independent Dir/Board Member	20/03/2014	20/05/2024

Jean-Jacques Bienaimé

Director/Board Member	29/11/2023	20/05/2024
Chief Executive Officer	15/05/2005	29/11/2023
Chairman	31/05/2015	29/11/2023
President	-	29/11/2023

Jeff Ajer

Corporate Officer/Principal	31/08/2005	19/05/2024
Sales & Marketing	31/08/2005	-
Corporate Officer/Principal	31/07/2005	-

Philip Lo Scalzo

Compliance Officer	21/11/2012	31/12/2023
General Counsel	15/12/2010	21/11/2012

Debra Charlesworth

Public Communications Contact

31/12/2022

Michael Grey

Director/Board Member	14/12/2005	24/05/2021
Independent Dir/Board Member	12/09/2011	24/05/2021

Alan J. Lewis

Director/Board Member	31/05/2005	26/05/2020
Independent Dir/Board Member	12/09/2011	26/05/2020

Robert Baffi

Corporate Officer/Principal

30/04/2000

03/05/2020

Dan Spiegelman

Director of Finance/CFO

29/05/2012

28/01/2020

Richard Ranieri

Human Resources Officer

03/09/2013

31/12/2018

Barrie J. Carter

Corporate Officer/Principal

31/01/2013

30/11/2018

Kathryn Falberg

Director/Board Member

17/07/2016

31/05/2017

Ken Bate

Director/Board Member	31/08/2010	31/12/2016
Independent Dir/Board Member	31/08/2010	31/12/2016

Leonard Post

Chief Tech/Sci/R&D Officer

31/12/2009

31/05/2016

Dan Oppenheimer

Corporate Officer/Principal

30/06/2002

31/05/2016

Pierre LaPalme

Director/Board Member	31/12/2014	31/05/2016
Chairman	31/07/2004	31/05/2015
Independent Dir/Board Member	31/07/2004	09/05/2012

Vassiliki Economides

Corporate Officer/Principal

28/02/2015

31/05/2016

David J. Ellam

Corporate Officer/Principal

31/12/2009

31/12/2015

Joshua Grass

Public Communications Contact	31/12/2001	10/05/2009
Corporate Officer/Principal	10/05/2009	31/12/2015

William Young

Director/Board Member	21/09/2010	11/11/2015
Independent Dir/Board Member	21/09/2010	11/11/2015

Edward Conner

Chief Tech/Sci/R&D Officer

30/09/2013

31/10/2014

Suyash Prasad

Corporate Officer/Principal

30/11/2010

31/01/2014

Mark Wood

Human Resources Officer	30/04/2004	31/05/2013
Public Communications Contact	12/09/2011	31/05/2013

Stephen Aselage

Corporate Officer/Principal

30/06/2005

31/08/2012

Jeffrey Cooper

Director of Finance/CFO

30/09/2003

30/04/2012

Jackie Walling

Chief Tech/Sci/R&D Officer

24/05/2010

29/02/2012

Joseph Klein

Director/Board Member

31/05/2005

18/03/2010

Alejandro Dorenbaum

Chief Tech/Sci/R&D Officer

31/12/2008

Henry Fuchs

Chief Tech/Sci/R&D Officer

28/02/2009

Emil Kakkis

Chief Tech/Sci/R&D Officer

31/08/1998

26/02/2009

S. Michael Imperiale

Corporate Officer/Principal

31/12/2008

Eduardo Von Pervieux

Chief Tech/Sci/R&D Officer

24/05/2010

Gordon Vehar

Chief Tech/Sci/R&D Officer

27/01/2008

Bill Aliski

Corporate Officer/Principal

30/11/2005

31/12/2007

Lewis Chapman

Sales & Marketing

30/06/2007

Erich Sager

Director/Board Member

31/10/1997

28/02/2006

John Ditton

Sales & Marketing

31/12/2005

Christopher Starr

Chief Tech/Sci/R&D Officer	-	31/12/2005
Founder	31/12/1996	31/12/2005

Louis Drapeau

Chief Executive Officer	31/12/2003	31/05/2005
Director of Finance/CFO	31/12/2003	22/08/2005

Kim Tsuchimoto

Comptroller/Controller/Auditor	31/01/1997	31/05/2005
Treasurer	31/01/1997	31/05/2005

Vimal Srivastava

Corporate Officer/Principal

31/12/2004

John Urquhart

Director/Board Member

30/06/2003

31/12/2004

Todd C. Zankel

Chief Tech/Sci/R&D Officer

31/12/1996

31/12/2004

David Scott Geyer

Corporate Officer/Principal

31/01/2004

Robert A. Heft

Corporate Officer/Principal

31/12/2000

31/12/2003

Vijay Samant

Director/Board Member

31/12/2001

31/12/2003

Matt Patterson

Corporate Officer/Principal

31/12/1997

31/12/2003

Fredric D. Price

Chief Executive Officer	31/12/1999	31/12/2003
Chairman	31/12/1999	31/12/2003

Franz L. Cristiani

Director/Board Member

30/06/2002

Raymond Anderson

Chief Operating Officer	31/05/1998	31/12/2001
Director of Finance/CFO	31/05/1998	31/12/2000

Ansbert Gadicke

Director/Board Member

31/12/1996

31/12/2000

Amy Lea Waterhouse

General Counsel

31/12/1999

Steven Jungles

Corporate Officer/Principal

31/05/1999

Stuart J. Swiedler

Chief Tech/Sci/R&D Officer

31/05/1998

Grant W. Denison

Director/Board Member	20/03/1997	-
Chief Executive Officer	20/03/1997	31/12/1999
Founder	20/03/1997	-

Zhong Qi Shao

Corporate Officer/Principal

Lisa M. Bell

General Counsel

Jeffrey Landau

Chief Administrative Officer

Charles Olson

Corporate Officer/Principal

Valerie Smith

Corporate Officer/Principal

Mary Newman

General Counsel

Bob Purcell

Public Communications Contact

12/09/2011

Reinhard Gabathuler

Chief Tech/Sci/R&D Officer

John Edward Ilett

Director/Board Member	-	-
General Counsel	-	-

Andria Langenberg

Chief Operating Officer	-	-
Chief Tech/Sci/R&D Officer	-	-

Kevin Scott

Corporate Officer/Principal

Steve Glass

Corporate Officer/Principal

Barbara Wuebbels

Corporate Officer/Principal

Monica Miller

Corporate Officer/Principal

Philip A. Pemberton

Corporate Officer/Principal

Dawn Blessing

Corporate Officer/Principal

Gwynn Williams

Director/Board Member

Leonid Katz

Corporate Officer/Principal

Age distribution of managers

Parity Men Women

Male	18
Female	6

Of which Executive Committee

Male	7
Female	2

Of which Directors

Male	9
Female	2

Revisions

Révisions CA 1 an

Révisions CA 4 mois

Révisions CA 1 mois

Révisions BNA 1 an

Révisions BNA 4 mois

ESG MSCI

Environnement

Social

Gouvernance

Polémique

Controverses Ethiques

Controverses sur les droits de l'Homme

Controverses Subventions fiscales

Conforme à la finance Islamique

BioMarin Pharmaceutical Inc. (BioMarin) is a biotechnology company, which is engaged in developing and commercializing therapies that address the root cause of genetic conditions. BioMarin's commercial products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Palynziq (pegvaliase-pqpz), Brineura (cerliponase alfa), Aldurazyme (laronidase), Roctavian (valoctocogene roxaparvovec), Kuvan (sapropterin dihydrochloride), and Voxzogo (vosoritide). Vimizim is an enzyme replacement therapy for the treatment of MPS IVA, a lysosomal storage disorder. The Roctavian is an adeno associated virus (AAV5) vector gene therapy designed to restore factor VIII plasma concentrations in patients with severe hemophilia A. Voxzogo is a once daily injection analog of C-type Natriuretic Peptide (CNP) for the treatment of achondroplasia. Brineura is a recombinant human tripeptidyl peptidase 1 (TPP1) for the treatment of patients with CLN2, a form of Batten disease.

Employees

3,040

Sector

Pharmaceuticals

Calendar

02-24 - Q4 2025 Earnings Release (Projected)

More about the company